Cluster-immunotherapy in allergic rhinoconjunctivitis: A review of an innovative, new therapeutic approach;Die Cluster-immuntherapie bei allergischer rhinokonjunktivitis: Übersicht über ein innovatives Therapiekonzept

Allergologie

Volumn 32, Issue 11, 2009, Pages 433-440

  Pfaar, O ^a,b   Hormann K ^a   Klimek, L ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Zentrum fur Rhinologie und Allergologie   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Cluster immunotherapy; Cluster protocols; Specific hyposensitization; Specific immunotherapy

Indexed keywords

ALLERGEN;

ALLERGY; CLINICAL PROTOCOL; CONFERENCE PAPER; IMMUNOGENICITY; IMMUNOTHERAPY; PROVOCATION TEST; RHINOCONJUNCTIVITIS;

EID: 74749094743     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper: Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998; 53: 1-42.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van WC, Agache I, it-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, vanWijkRG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, Van CP, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, nnesi-Maesano I, Bateman ED, Ben KA, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G,Williams D. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with theWorld Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 (Suppl 86): 8-160.
3. Pfaar O, Klimek L. Specific immunotherapy for allergic rhinitis. Current methods and innovative developments. HNO. 2008; 56: 764-775.
4. Kleine-Tebbe J, Fuchs T, Klimek L, Kühr J, Kunkel G, Lepp U, Niggemann B, Rakoski J, Renz H, Saloga J, Simon J. Spezifische Immuntherapie bei IgE-vermittelten allergischen Atemwegserkrankungen. Deutsches Ärzteblatt. 2003; 100: 335-339.
5. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006; 97: 126-137.
6. Pfaar O, Klimek L. Die Cluster-Immuntherapie bei allergischer Rhino-Konjunktivitis - eine Übersicht über ein neues Therapiekonzept. Hautarzt. 2006; 57: 875-880.
7. Freeman J. Rush inoculation with special reference to hay fever treatment. Lancet. 1930; 1: 744.
8. Malling H, Weeke B. Position paper: Immunotherapy. The European Academy of Allergology and Clinical Immunology (EAACI). Allergy. 1993; 48: 7-35.
9. Weber RW, Vaughan TR, Dolen WK. A10-year review of adverse reactions to immunotherapy. J Allergy Clin Immunol. 1988; 81: 295.
10. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy. 1995; 50: 405-413.
11. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 2000; 23: 323-332.
12. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsbl-Gesundheitsforsch- Gesundheitsschutz. 2001; 44: 709-718.
13. Kleine-Tebbe J, Bergmann KC, Friedrichs F, Fuchs T, Jung K, Klimek L, Kühr J, LässigW, Jepp U, Niggemann B, Rakoski J, Rebien W, Renz H, Saloga J, Simon J, Sitter H, Virchow C, Worm M. Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J. 2006; 15: 56-74.
14. Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol. 1981; 68: 460-470.
15. Tabar AI, Muro MD, Garcia BE, Alvarez MJ, Acero S, Rico P, Olaguibel JM. Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. J Investig Allergol Clin Immunol.1999; 9: 155-164.
16. Moreno C, Fernandez-Tavora L, Acero S, Alonso MD, Barahona MJ, Blanco R, Cistero A, Conde J, Fernandez J, Fernandez S, Fernandez-Rivas M, Garcia BE, Garcia-Rodriguez R, Camacho E, Gonzalez-Quevedo T, Gonzalo A, Guardia P, Sanchez-Cano M, Tabar AI, de la Torre TF. Tolerance of a cluster schedule on the treatment of seasonal allergic respiratory disease with pollen extracts quantified in mass units. J Investig Allergol Clin Immunol. 2003; 13: 221-227.
17. Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B, Aldunate MT, Martin S, Marcotegui F. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005; 116: 109-118.
18. Schubert R, Eickmeier O, Garn H, Baer PC, Mueller T, Schulze J, Rose MA, Rosewich M, Renz H, Zielen S. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009; 148: 251-260.
19. Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, Moreno AC, Shah K, Mosges R. Safety of two Cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol. 2009; 150: 102-108.
20. Subiza J, Feliu A, Subiza JL, Uhlig J, Fernandez-Caldas E. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy. 2008; 38: 987-994.
21. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000; 30: 1423-1429.
22. Hansen I, Hormann K, Stuck BA, Schneider-Gene S, Mosges R, Klimek L. Cluster-Immuntherapie bei allergischer Rhinokonjunktivitis. Allergologie. 2002; 25: 549-556.
23. Serrano P, Algorta J, Martinez A, Gonzalez-Quevedo T, Velazquez E, Diaz M. Prospective safety study of immunotherapy administered in a cluster schedule. J Investig Allergol Clin Immunol. 2004; 14: 312-319.
24. Pfaar O, Moesges R, Hörmann K, Klimek L. Die Cluster-Immuntherapie bei der perennialen allergischen Rhinitis: Sicherheitsaspekte der Anwendung von einem Milben-Depot-Allergen-Präparat. HNO. 2009 (in Druck).
25. Pfaar O, Mösges R, Hörmann K, Klimek L. Safety aspects of cluster-immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2009; accepted for publication.
26. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol. 2006; 139: 153-158.
27. Hansen I, Hormann K, Stuck BA, Schneider-Gene S, Mosges R, Klimek L. Cluster-Immuntherapie bei saisonaler allergischer Rhinitis. Erfahrungen zur Sicherheit einer Initialtherapie mit Depot-Allergoiden (Purethal). Laryngorhinootologie. 2003; 82: 558-563.
28. Mauro M, Russello M, Alesina R, Sillano V, Alessandrini A, Dama A, Passalacqua G, Senna G. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol. 2006; 38: 31-34.